Semaglutide and Obesity: A New Hope for Patients with Cardiovascular Disease
- Health Communicator
- Jun 22
- 5 min read
Updated: Sep 3
AUDIO:
This article summarizes the most important findings for patients who are overweight or obese and have cardiovascular disease but do not have diabetes. It is based on the large international clinical trial SELECT ("Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial"), published in July 2024 in the prestigious scientific journal Nature Medicine (Volume 30, pp. 2049–2057).
The publication’s authors include leading scientists, physicians, and researchers in endocrinology, metabolism, and cardiology—among them Prof. Donna H. Ryan (Pennington Biomedical Research Center, USA), Prof. Ildiko Lingvay (University of Texas Southwestern Medical Center, USA), Prof. John Deanfield (University College London, UK), Prof. Steven Kahn (University of Washington, USA), as well as experts from Europe, North and South America, Asia, and the Middle East.
The goal of SELECT is to evaluate the effectiveness, safety, and impact of the medication semaglutide in people with obesity who do not have diabetes but are already at elevated cardiovascular risk—a topic of major importance in modern medicine.
